Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that can cause cancer—that may ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene - a gene that can cause cancer - that ...

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

Researchers have identified a mutation in a common oncogene that may play an important role in colon cancer. Their findings ...

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role ...

Daraxonrasib has received breakthrough therapy designation from the FDA for KRAS G12+, previously treated, metastatic ...

An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the ...

The Food and Drug Administration (FDA) has granted accelerated approval to Avmapki ™ (avutometinib) plus Fakzynja ™ (defactinib) for the treatment of adult patients with KRAS- ...